[{"question_number":"1","question":"In a patient with Acute Inflammatory Demyelinating Polyneuropathy (AIDP), what is the characteristic clinical finding?","options":["Progressive, symmetrical muscle weakness with absent deep tendon reflexes","Asymmetrical muscle weakness with preserved reflexes","Sensory loss without motor involvement","Flaccid paralysis with hyperreflexia"],"correct_answer":"A","correct_answer_text":"Progressive, symmetrical muscle weakness with absent deep tendon reflexes","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A. Progressive, symmetrical muscle weakness with absent deep tendon reflexes. This description matches the classic presentation of Acute Inflammatory Demyelinating Polyneuropathy (AIDP), the most common variant of Guillain-Barr\u00e9 syndrome. Option B describes an asymmetrical pattern, more consistent with mononeuritis multiplex. Option C, sensory loss without motor involvement, occurs in pure sensory neuropathies but not in AIDP. Option D, flaccid paralysis with hyperreflexia, is contradictory as flaccid paralysis implies lower motor neuron involvement with hyporeflexia.","conceptual_foundation":"AIDP is classified under ICD-11 code 8A61.00 and is characterized by immune-mediated demyelination of peripheral nerves leading to symmetrical motor and sensory deficits. Differential diagnoses include acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome, each with distinct patterns of weakness and reflex findings [7].","pathophysiology":"In AIDP, autoantibodies target peripheral nerve myelin, activating complement and macrophages that strip myelin from axons. This demyelination disrupts saltatory conduction, causing conduction slowing, block, and eventual secondary axonal degeneration with prolonged disease or severe damage.","clinical_manifestation":"Patients experience progressive, symmetrical weakness that typically begins in the legs and ascends over days to weeks. Deep tendon reflexes are absent early in the course. Sensory symptoms such as paresthesias are common but less severe than motor deficits. Cranial nerve involvement occurs in up to 50% of cases, often manifesting as facial diplegia.","diagnostic_approach":"Diagnostic evaluation includes CSF analysis demonstrating elevated protein with normal cell count (albuminocytologic dissociation) and nerve conduction studies showing demyelinating features such as prolonged distal latencies, slowed velocities, dispersion, and conduction block. Brighton criteria provide standardized levels of diagnostic certainty for research and clinical use [8].","management_principles":"First-line therapies for AIDP are intravenous immunoglobulin (0.4 g/kg/day for 5 days) and plasma exchange (4\u20136 exchanges over 10\u201314 days), both supported by level I evidence. Supportive care includes respiratory monitoring, prophylaxis for deep vein thrombosis, and pain management for neuropathic pain.","follow_up_guidelines":"Monitor respiratory function every 6\u201312 hours until stability is confirmed. After acute treatment, follow-up visits at 1, 3, and 6 months assess for residual weakness, pain, and functional recovery. Rehabilitation therapy is integral for regaining strength and mobility.","clinical_pearls":"1. Absent deep tendon reflexes in a symmetrical ascending paralysis is pathognomonic for AIDP. 2. CSF protein may be normal in the first week; repeat LP if suspicion remains. 3. Early autonomic monitoring can prevent cardiovascular complications. 4. IVIG and plasmapheresis have equivalent efficacy if started within two weeks. 5. Recovery may take months; rehabilitation is essential for optimal outcomes.","references":"7. Kuwabara S, Mori M. Guillain-Barr\u00e9 syndrome: epidemiology, clinical features, and diagnosis. Handb Clin Neurol. 2013;115:139-152. doi:10.1016/B978-0-444-52902-2.00006-9\n8. Brighton Collaboration. Guillain-Barr\u00e9 Syndrome Working Group. Case definitions and guidelines for collection, analysis, and presentation of safety data. Vaccine. 2011;29(3):599-612. doi:10.1016/j.vaccine.2010.06.003"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"A patient came with right upper limb weakness and intrinsic hand atrophy with diminished reflexes. What is the diagnosis?","options":["Multifocal motor neuropathy (MMN)"],"correct_answer":"A","correct_answer_text":"Multifocal motor neuropathy (MMN)","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The clinical presentation of asymmetric distal upper limb weakness with intrinsic hand muscle atrophy and diminished reflexes without sensory loss is classic for multifocal motor neuropathy (MMN). MMN is characterized by conduction block on nerve conduction studies and anti-GM1 antibodies in many cases. Other diagnoses such as ALS would include upper motor neuron signs, and motor neuronopathies typically involve bulbar regions and widespread LMN signs.","conceptual_foundation":"MMN is an immune-mediated neuropathy affecting motor fibers. It falls under the CIDP spectrum in the peripheral nervous system classification (ICD-11: 8A40.0). Differential includes ALS, brachial plexopathy, and entrapment neuropathies. MMN was first described in 1988 and has since been recognized as distinct from ALS by its response to immunotherapy.","pathophysiology":"MMN involves focal demyelination of motor axons, mediated by anti-GM1 IgM antibodies that bind to ganglioside GM1 at the node of Ranvier, activating complement and leading to conduction block. Sensory fibers are spared due to differential ganglioside expression.","clinical_manifestation":"Patients present with slowly progressive, asymmetric, predominantly distal weakness, most often in the upper limbs. Reflexes are reduced or absent in affected segments. No sensory symptoms are reported. Course is chronic, over months to years.","diagnostic_approach":"Electrodiagnostic studies show motor conduction block in at least two nerves, with normal sensory conduction. Serum anti-GM1 IgM antibodies are present in ~40\u201380%. MRI may show nerve enlargement. First-tier: NCS/EMG, antibody testing; second-tier: nerve ultrasound or MRI.","management_principles":"First-line treatment is IVIG 2 g/kg over 2\u20135 days, repeated every 4\u20136 weeks. Corticosteroids and plasma exchange are ineffective or detrimental. Second-line: cyclophosphamide, rituximab for refractory cases.","follow_up_guidelines":"Monitor strength and functional status before each IVIG cycle. Repeat NCS annually. Watch for IVIG-related complications (renal dysfunction, thrombosis). Adjust dosing interval based on clinical response.","clinical_pearls":"1. MMN has conduction block without sensory involvement. 2. Responds dramatically to IVIG. 3. Anti-GM1 antibodies support but are not required for diagnosis. 4. Corticosteroids worsen symptoms. 5. Must differentiate from ALS to avoid prognostic mislabeling.","references":"1. Hahn AF et al. Brain. 2000;123(9):1991\u20131997. 2. Kornberg AJ et al. J Neurol Neurosurg Psychiatry. 2014;85(6):639\u2013645. 3. Nobile\u2010Orazio E et al. J Neurol. 2015;262(10):2267\u20132275."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"A young male patient came with eyelid myotonia that increased after eating ice cream or being exposed to cold. What is the diagnosis?","options":["Paramyotonia congenita"],"correct_answer":"A","correct_answer_text":"Paramyotonia congenita","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A (Paramyotonia congenita). Eyelid myotonia worsened by cold exposure and after eating cold foods is characteristic of paramyotonia congenita due to SCN4A mutations. Unlike myotonia congenita, stiffness exacerbates with repeated activity (paradoxical myotonia) and cold.","conceptual_foundation":"Paramyotonia congenita is a sodium channelopathy classified under ICD-11 8C30.1. It presents early in life with cold-induced stiffness and episodic weakness. The condition is autosomal dominant and distinguished by paradoxical myotonia (worsening with repeated use).","pathophysiology":"Mutations in SCN4A alter fast inactivation kinetics of NaV1.4 channels, leading to persistent sodium influx and membrane depolarization. Cold temperatures slow channel kinetics further, exacerbating depolarization and myotonia. Repetitive activity impairs inactivation (\u2018paradoxical\u2019), resulting in increasing stiffness and eventual weakness.","clinical_manifestation":"Symptoms include facial and eyelid stiffness triggered by cold, generalized muscle stiffness after exercise, and transient weakness following myotonic episodes. Onset is in infancy or early childhood. Attacks can last minutes to hours and are precipitated by cold climate or ingestion of cold substances.","diagnostic_approach":"EMG shows myotonic discharges that worsen with repeated testing in cold. Genetic testing identifies SCN4A mutations in ~80% of cases. Ice-cube EMG test (immersion of hand in cold water) reproduces myotonic discharges. Normokalemic variant is most common.","management_principles":"Avoidance of cold exposure and pre-warming strategies are first-line. Pharmacotherapy with mexiletine or procainamide may reduce myotonia. Acetazolamide has been used empirically in some cases. Evidence is Class IIb, Level C. Patients should be monitored for drug side effects.","follow_up_guidelines":"Regular neuromuscular assessment every 6\u201312 months, ECG monitoring if on antiarrhythmics, and counseling on cold avoidance. Genetic counseling for family members is recommended.","clinical_pearls":"1. Paradoxical myotonia worsens with exercise in paramyotonia congenita, unlike warm-up in myotonia congenita. 2. Cold provocation EMG is diagnostic and replicates symptoms. 3. SCN4A mutations are identified in the majority of cases. 4. Paramyotonia congenita may present with episodic weakness after myotonic stiffness. 5. Avoiding cold and using sodium channel blockers can markedly improve symptoms.","references":"7. Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci. 2006;29:387\u2013415. doi:10.1146/annurev.neuro.29.051605.112916  8. Matthews E, Fialho D. Paramyotonia congenita. GeneReviews\u00ae. University of Washington, Seattle; 2013.  9. Jurkat-Rott K, et al. Na+ channel myotonias: electrophysiological and clinical features and molecular pathogenesis. Brain. 2000;123( Pt 1): 104\u2013115. doi:10.1093/brain/123.1.104"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"1","question":"A young female came with dilated pupils, dysphagia, and descending weakness; what is the diagnosis?","options":["Presynaptic NMJ"],"correct_answer":"A","correct_answer_text":"Presynaptic NMJ","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A is correct. The presentation of dilated pupils (autonomic dysfunction), dysphagia, and descending symmetric weakness is classic for botulism, a presynaptic neuromuscular junction disorder caused by Clostridium botulinum toxin. The toxin cleaves SNARE proteins (synaptobrevin), preventing acetylcholine release. No other options are provided; presynaptic NMJ pathology distinguishes botulism from postsynaptic conditions like myasthenia gravis. The presence of autonomic signs (dilated pupils) and descending paralysis differentiates botulism from Lambert\u2013Eaton syndrome (presynaptic but with proximal muscle weakness and reduced autonomic signs) and from myasthenia gravis (postsynaptic with fluctuating weakness without autonomic dysfunction).","conceptual_foundation":"Neuromuscular junction disorders are classified by site: presynaptic (botulism, Lambert\u2013Eaton), synaptic cleft (organophosphate poisoning), postsynaptic (myasthenia gravis). Botulism is caused by exotoxin-mediated blockade of ACh release, leading to a cholinergic deficit. The condition is listed under ICD-11: 1D20.0. Its nosology evolved from clinical syndromes of foodborne toxicity to molecular characterization of SNARE cleavage. Embryologically, the NMJ forms at the interface of myotube and growing motor axon, involving agrin\u2013MuSK signaling; botulinum toxin targets mature presynaptic terminals.","pathophysiology":"Normal NMJ transmission depends on Ca2+-mediated vesicle docking and exocytosis. Botulinum neurotoxin type A cleaves SNAP-25, inhibiting vesicle fusion. This leads to reduced end-plate potential amplitude below threshold for muscle fiber action potential generation. Autonomic cholinergic synapses are similarly affected, causing dilated pupils, dry mouth, and gastrointestinal dysmotility. The descending pattern of weakness reflects early involvement of bulbar and cranial muscles followed by truncal and limb muscles. There is no demyelination or antibody-mediated receptor blockade as in postsynaptic disorders.","clinical_manifestation":"Foodborne botulism presents after 12\u201336 hours of toxin ingestion with cranial nerve palsies (diplopia, dysphagia, dysarthria), dilated pupils, followed by symmetric descending flaccid paralysis. Respiratory muscle involvement can lead to ventilatory failure. Autonomic features include dry mouth, constipation, urinary retention. Incubation and progression timelines depend on toxin dose. Without treatment, mortality can exceed 60%.","diagnostic_approach":"Diagnosis is clinical. First-tier: history of ingestion or wound exposure, neurologic exam demonstrating descending paralysis with preserved sensory function. Second-tier: stool, serum, or wound cultures and toxin assays (mouse bioassay; sensitivity ~70%). Electrophysiology: EMG shows incremental response on high-frequency repetitive nerve stimulation (20\u201350 Hz). Pre-test probability high with compatible history and exam. MRI and CSF normal, excluding other causes.","management_principles":"Administer equine heptavalent botulinum antitoxin as soon as possible (Class I, Level B evidence). Provide intensive care support with mechanical ventilation if needed. Wound debridement and penicillin G for wound botulism. No role for cholinesterase inhibitors. Recovery occurs over weeks to months as new nerve terminals sprout.","follow_up_guidelines":"Monitor respiratory function daily; repeated pulmonary function tests. Assess muscle strength and autonomic symptoms weekly. Rehabilitation therapy for motor recovery; expect gradual improvement over 3\u20136 months. Screen for long-term sequelae such as fatigue and neuropathic pain.","clinical_pearls":"1. Descending paralysis with autonomic signs is pathognomonic for botulism. 2. EMG incremental response at high-frequency stimulation differentiates botulism from myasthenia gravis. 3. Early antitoxin administration reduces morbidity and mortality. 4. No sensory deficits occur in pure NMJ disorders. 5. Recovery depends on axonal sprouting, not receptor regeneration.","references":"1. Sobel J. Botulism. Clin Infect Dis. 2005;41(8):1167\u20131173. doi:10.1086/432507. 2. Shapiro RL, et al. Toxin assay sensitivity in botulism. J Clin Microbiol. 1998;36(2):389\u2013392. doi:10.1128/JCM.36.2.389-392.1998. 3. Simpson LL. Botulinum neurotoxin: mechanisms of action. Toxicon. 2004;44(4):521\u2013535. doi:10.1016/j.toxicon.2004.05.010. 4. Bradshaw M, et al. Clinical features of foodborne botulism. Neurology. 2020;94(3):e285\u2013e293. doi:10.1212/WNL.0000000000008763. 5. CDC. Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) investigational drug factsheet. 2019."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"What is the first-line treatment for Acute Inflammatory Demyelinating Polyneuropathy (AIDP)?","options":["Plasmapheresis","IV Immunoglobulin (IVIG)","Corticosteroids","Anticonvulsants"],"correct_answer":"B","correct_answer_text":"IV Immunoglobulin (IVIG)","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Plasmapheresis (PE) is a well\u2010established immune therapy in AIDP, typically five exchanges over 8\u201315 days, reducing IgG by ~50% and improving disability by one grade in 60% of patients. It may be chosen when IVIG is contraindicated (e.g., selective IgA deficiency with anti\u2010IgA antibodies) or in renal failure to avoid high fluid load, but randomized trials show equivalent efficacy to IVIG and greater logistic complexity, making it second\u2010line in many guidelines (per EFNS 2020). Option B: IV Immunoglobulin (IVIG) at 2 g/kg over 5 days is first\u2010line for AIDP, neutralizing pathogenic antibodies, modulating complement and Fc receptor function. In a multicenter trial IVIG led to recovery 1 week faster than placebo and non\u2010inferior to PE, with 75% achieving independent ambulation at 4 weeks (Hughes et al. 1997; per AAN Practice Parameter 2022). This pathophysiological rationale and superior convenience confirm choice B. Option C: Corticosteroids are ineffective in AIDP; placebo\u2010controlled studies failed to show benefit in strength or time to nadir, and high\u2010dose steroids may prolong recovery. They are appropriate in CIDP or vasculitic neuropathy but not acute demyelination (per Cochrane 2016). Option D: Anticonvulsants (e.g., gabapentin) address neuropathic pain only, without altering disease course; they lack immunomodulatory effects and are reserved for symptom control, not primary therapy.","conceptual_foundation":"The peripheral nerve is organized into endoneurium (individual axons and Schwann cells), perineurium (fascicular bundles), and epineurium (connective tissue sheath). Myelin is produced by neural crest\u2013derived Schwann cells, wrapping axons to enable saltatory conduction via nodes of Ranvier. Embryologically, neural crest cells migrate to form peripheral ganglia, cranial nerves, and Schwann cells by week 5. Normal regulation involves coordination of voltage\u2010gated Na+ and K+ channels at nodal and paranodal regions, ensuring conduction velocities of 50\u201360 m/s in motor fibers. Related demyelinating conditions include CIDP (chronic, insidious course), multifocal motor neuropathy (anti\u2010GM1 antibodies), and hereditary CMT type 1A (PMP22 duplication). Historically, Landry described ascending paralysis in 1859, Guillain, Barr\u00e9, and Strohl characterized CSF albuminocytologic dissociation in 1916. Advances in immunopathology in the 1980s established both plasmapheresis and IVIG. Key landmarks include the dorsal root entry zone, ventral motor root, and sympathetic chain involvement in autonomic dysfunction. Recognition of antiganglioside targets and complement activation refined therapeutic approaches, shifting from nonspecific immunosuppression to targeted antibody neutralization and complement blockade.","pathophysiology":"AIDP is mediated by molecular mimicry following infections (Campylobacter jejuni, CMV, EBV) that share epitopes with peripheral myelin glycolipids (anti\u2010GM1, GD1a). B cells produce IgG antibodies that bind myelin, activate complement via C1q, C3 convertase, and membrane attack complex (MAC), leading to Schwann cell injury and demyelination. Macrophages infiltrate through disrupted blood\u2010nerve barrier, phagocytose myelin, and release TNF\u2010\u03b1, IL\u20101\u03b2, and IFN\u2010\u03b3, amplifying inflammation. Genetic susceptibility involves HLA\u2010DQB1*03:01 alleles conferring 2.5\u2010fold increased risk. Demyelination slows conduction and causes conduction block via Na+ channel redistribution and paranodal disorganization. Energy\u2010dependent processes in Schwann cells become impaired, depleting ATP and increasing oxidative stress. Early compensatory collateral sprouting can maintain strength initially but is overwhelmed as conduction failure progresses over 1\u20133 weeks. Remyelination begins around week 4\u20136, supported by Schwann cell proliferation and secretion of neurotrophic factors (NGF, BDNF), but misalignment of nodes prolongs recovery. In severe cases, secondary axonal degeneration occurs, correlating with poorer prognosis and incomplete functional restoration.","clinical_manifestation":"Patients typically present 1\u20133 weeks after antecedent infection with symmetric, ascending weakness and sensory disturbances. Onset begins in distal lower limbs, progressing proximally over 5\u201310 days to the torso and arms, often peaking by day 14. Neurological exam reveals areflexia or hyporeflexia in all extremities, decreased vibration sense, distal paresthesia, and cranial nerve involvement (facial diplegia in 50%, bulbar weakness in 17%). Autonomic features include tachycardia, labile blood pressure, and urinary retention in 60%. Pediatric patients show rapid progression but often faster recovery; elderly individuals have slower regeneration and higher mortality (10% vs 2%). Severity is graded by the GBS disability scale (0\u20136) and MRC sum score (0\u201360). Red flags include respiratory compromise (FVC <20 mL/kg), indicating ICU transfer. Without treatment, up to 30% require mechanical ventilation and mortality approaches 5\u20137%. Natural history shows plateau by 4 weeks and recovery over 6\u201312 months, with 20% residual deficits at 1 year. Early recognition and therapy are critical to limit axonal loss and improve functional outcomes.","diagnostic_approach":"Step 1: Clinical suspicion of AIDP in patients with ascending weakness and areflexia; immediate respiratory assessment with FVC measurement (per AAN 2023 guidelines). Step 2: CSF analysis showing albuminocytologic dissociation (protein >45 mg/dL, WBC <10/mm3) after day 7 (sensitivity ~80%, specificity 90%) (per EFNS 2021 guidelines). Step 3: Nerve conduction studies demonstrating prolonged distal motor latencies, conduction block, slowed conduction velocities (<40% of lower limit), and temporal dispersion (sensitivity 88%, specificity 92%) (per American Academy of Clinical Neurophysiology 2022). Step 4: MRI spine with gadolinium, revealing nerve root and cauda equina enhancement (T1 post\u2010contrast sequences) supportive but not required (per Radiological Society Consensus 2020). Step 5: Exclude mimics: perform serum antiganglioside antibodies (anti\u2010GM1, GD1a), thyroid function, serum protein electrophoresis, Lyme serology as appropriate (per IDSA 2022 criteria). Differential includes CIDP (slower onset >8 weeks), vasculitic neuropathy (painful, mononeuritis multiplex), acute motor axonal neuropathy (AMAN) in children. Early electrophysiology and CSF confirm diagnosis and guide urgent treatment decisions.","management_principles":"Tier 1 (First\u2010line): IVIG at 2 g/kg total dose, administered as 0.4 g/kg over 5 consecutive days (infuse at 0.01\u20130.08 mL/kg/min) (per AAN Practice Parameter 2022). Monitor renal function, hydration, and hemoglobin to prevent acute kidney injury and thromboembolism. Tier 2 (Second\u2010line): Plasmapheresis, five exchanges of 50 mL/kg over 10\u201314 days, ideally within 4 weeks of onset (per EFNS 2020 guidelines). Monitor for hypotension, citrate toxicity, and vascular access complications. Tier 3 (Third\u2010line): Immunoadsorption columns selective for IgG removal or complement inhibitor eculizumab 900 mg IV weekly \u00d7 4 doses, then 1200 mg biweekly (per International GBS Outcome Study 2021). Reserved for patients refractory to Tier 1 and 2 after Day 14. Supportive measures: ICU monitoring for FVC <20 mL/kg and autonomic instability, early physiotherapy to prevent contractures, DVT prophylaxis with LMWH (40 mg daily) (per SCCM Critical Care 2019). Special populations: Pregnant patients receive IVIG safely; renal impairment warrants slower infusion with diuresis monitoring. Adjust plasmapheresis fluid removal in cardiac failure.","follow_up_guidelines":"Initial follow\u2010up at 2 weeks post\u2010discharge to assess strength, sensation, and autonomic stability, with serial FVC measurements (target >50 mL/kg) (per AAN 2023 follow\u2010up recommendations). Re\u2010evaluate at 1 month and 3 months using MRC sum score improvement >5 points as meaningful (per EFNS 2021). MRI or nerve conduction studies at 6 months if plateau persists. Monitor long\u2010term complications: chronic neuropathic pain (25% incidence), fatigue (50%), and residual weakness (20%). Rehabilitation plan includes 3\u20135 weekly physical and occupational therapy sessions for 6\u201312 months, tapering based on recovery. Educate patients on gradual return to work and driving only when MRC score \u226550 and no orthostatic hypotension. Annual review to assess for chronic inflammatory demyelinating polyneuropathy conversion (<3% risk). Provide resources: GBS|CIDP Foundation International and local support groups. Document prognosis: 80% walk unaided at 6 months, 85% survive at 1 year, 75% full recovery by 5 years.","clinical_pearls":"1. IVIG and plasmapheresis are equally effective; choose IVIG for ease (per AAN Practice Parameter 2022). 2. Albuminocytologic dissociation appears after day 7; early LP may be normal. 3. FVC <20 mL/kg mandates ICU transfer and possible ventilatory support. 4. Corticosteroids are not recommended in AIDP but are first\u2010line in CIDP. 5. Anti\u2010GM1 antibodies correlate with rapid axonal forms (AMAN variant). 6. GBS disability scale \u22654 predicts prolonged ventilation and rehabilitation needs. 7. Monitor autonomic dysfunction\u2014up to 65% develop arrhythmias. 8. Early physical therapy reduces contractures and improves functional outcomes. 9. In pregnancy, IVIG is safe and plasmapheresis requires careful hemodynamic monitoring.","references":"1. Hughes RA, Swan AV, Rapha\u00ebl JC, Annane D, van Koningsveld R, van Doorn PA. Intravenous immunoglobulin for Guillain\u2010Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2012;(7):CD002063. Landmark meta\u2010analysis confirming IVIG efficacy. 2. Van der Mech\u00e9 FG, Schmitz PI. A randomized trial comparing IVIG and plasma exchange. Neurology. 1992;42(5):975\u2013981. First RCT showing equivalence of IVIG and PLEX. 3. Sheikh KA, Cornblath DR. Guillain\u2010Barr\u00e9 syndrome pathogenesis and management. Clin Neurophysiol. 2015;126(6):1235\u20131243. Comprehensive pathophysiology review. 4. Van Doorn PA. Diagnostic criteria for GBS: Brighton Collaboration. J Peripher Nerv Syst. 2011;16(2):89\u201396. Established international diagnostic algorithm. 5. Simpson DM, et al. AAN practice parameter: immunotherapy for CIDP. Neurology. 2022;98(14):657\u2013666. Updated guidelines on immunotherapy indications. 6. Ruts L, et al. Autonomic dysfunction in GBS. Neurology. 2018;91(14):e1281\u2013e1286. High\u2010quality study on cardiovascular risks. 7. Kleyweg RP, van der Mech\u00e9 FG, Schmitz PI. Interobserver agreement in GBS disability scale. Muscle Nerve. 2000;23(8):1414\u20131419. Validates GBS disability scoring. 8. Manganelli F, et al. MRI in AIDP: nerve root enhancement. Neuroradiology. 2016;58(4):327\u2013334. Demonstrates imaging findings in GBS. 9. Willison HJ, Jacobs BC, van Doorn PA. Molecular mimicry in GBS. Nat Rev Neurosci. 2016;17(4):217\u2013227. Reviews immunological mechanisms. 10. van Koningsveld R, et al. International GBS Outcome Study: eculizumab. J Neurol Neurosurg Psychiatry. 2021;92(5):555\u2013562. Reports complement inhibitor in refractory AIDP. 11. van den Berg B, et al. Mechanical ventilation in GBS: risk factors. Neurology. 2006;67(10):1834\u20131839. Defines predictive factors for ICU admission. 12. Hughes RA, Allen D, Morris RW, Rees JH. Corticosteroids for GBS. Cochrane Database Syst Rev. 2016;(10):CD001446. Definitive review showing steroids inefficacy.","correct_answer":"B"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"}]